FMP

FMP

Enter

EYEN - Eyenovia, Inc.

photo-url-https://financialmodelingprep.com/image-stock/EYEN.png

Eyenovia, Inc.

EYEN

NASDAQ

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

0.546 USD

-0.0074 (-1.36%)

About

ceo

Mr. Michael M. Rowe

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development progr...

CIK

0001682639

ISIN

US30234E1047

CUSIP

30234E104

Address

295 Madison Avenue

Phone

917 289 1117

Country

US

Employee

57

IPO Date

Jan 25, 2018

EYEN Financial Summary

CIK

0001682639

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

30234E104

ISIN

US30234E1047

Country

US

Price

0.55

Beta

1.74

Volume Avg.

1.66M

Market Cap

46.67M

Shares

-

52-Week

0.37-2.57

DCF

-0.03

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.71

P/B

-

Website

https://www.eyenovia.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest EYEN News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep